Get to know the Versiti Clinical Trials executive leadership team and learn more about our commitment to unparalleled clinical trial services.
President and CEO, Versiti
Chris was appointed President and CEO of Versiti on Feb. 1, 2017, after a career spanning more than 20 years exclusively in healthcare. He is first and foremost a patient and blood donor advocate who is passionate about the employee experience of more than 2,000 Versiti colleagues across Illinois, Indiana, Michigan, Ohio, Texas and Wisconsin. Together with the Versiti leadership team, Chris has strengthened Versiti’s culture and stoked the flame of blood health innovation.
EVP and Chief Laboratory Officer, Versiti
Brad joined Versiti in 2001 and spent the first 15 years of his Versiti career in Versiti Diagnostic Laboratories, where he developed formal processes for evaluating, approving and prioritizing innovative technologies and clinical assays into Diagnostic Labs, and led the early integration of clinical lab assets across Versiti’s footprint into a single operation. Throughout his career, he has developed broad executive leadership skills while ensuring robust governance mechanisms for both near-term performance and long-term strategic planning and execution, ultimately advancing our mission to drive blood health innovation.
Matthew Anderson, MD, PhD
VP and Medical Director of Diagnostic Laboratories, Versiti
Dr. Anderson provides clinical, strategic and regulatory oversight for Versiti Diagnostic Labs, including collaborations with academic and industry partners, to improve patient care through advances in laboratory medicine and genomics. Prior to joining Versiti, Dr. Anderson served as an assistant professor in the Department of Pathology at Stanford University School of Medicine, and as the assistant director of the Stanford Histocompatibility, Immunogenetics, and Disease Profiling Laboratory. Dr. Anderson is a graduate of the Medical Scientist Training Program at the Medical College of Wisconsin. He is board-certified in anatomic pathology, molecular genetic pathology and histocompatibility. His research interests include the use of next-generation sequencing technologies for clinical diagnostics and biomarker discovery.
Chief Operating Officer, Cenetron Diagnostics
Brandon has been with Cenetron for more than 15 years and has 25 years of experience in regulated and research environments. He earned an undergraduate degree at the University of Texas in biochemistry. Brandon has extensive laboratory management, regulatory and project management experience, in both point-of-care and phase I-IV clinical research capacities. Additionally, he has been trained as an emergency medical technician and is a certified Lean Six Sigma Green Belt.
Priscilla Short, BHA, CIP, CCRP
Executive Director, Salus IRB
Priscilla has more than 25 years of experience in the clinical trials industry, regulatory compliance, human research protection in all phases of clinical trials, operations and project management, and client relations. Priscilla joined Salus IRB in 2008 and led the effort in attaining the company’s initial AAHRPP accreditation. She has served as a site visitor for AAHRPP and on the Council on Accreditation for Alion Science & Technology’s HRPP accrediting program. She serves on a number of boards and committees, including the Consortium of Independent Review Boards (CIRB), Clinical Trials Transformation Initiative (CTTI) Steering Committee, and is a founding member of the Association of Clinical Research Professionals (ACRP) Central Texas Chapter. Priscilla is a member of Public Responsibility in Medicine and Research (PRIM&R), the Society for Clinical Research Associates (SoCRA), the Regulatory Affairs Professional Society (RAPS), the Drug Information Association (DIA), and the Association for Clinical Research Professionals (ACRP).
Vice President of Business Development, Versiti
Sean joined Versiti in 2019 and has more than 20 years of experience in clinical and research diagnostics. He earned an undergraduate degree in cytotechnology at the University of Akron. Sean’s business development experience includes launching oncology diagnostics services, driving reimbursement strategies with managed care organizations, strategic partnerships, advancement of translational research platforms, and clinical trial services across all phases.